VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 19, 2018 | $350,000 | Replaced |
| 1st Quarter - Amendment (this page) | Jan 15, 2019 | $470,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT BARNES | — |
| MICHAEL MATTOON | — |
| SAMANTHA VENTIMIGLIA | — |
Health Issues HCR
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT BARNES | — |
| MICHAEL MATTOON | — |
| SAMANTHA VENTIMIGLIA | — |
Medicare/Medicaid MMM
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT BARNES | — |
| MICHAEL MATTOON | — |
| SAMANTHA VENTIMIGLIA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.